Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jul 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-07-01

Reporting Person: KINGSLEY ALFRED D (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-01	Stock Option (right to buy)	$2.86	A	80000	Acquired	2031-07-01	Common Shares (80000)	Direct

Footnotes

F1: Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer.